logo-loader
HealthPharma & Biotech
Calithera Biosciences Inc

Calithera Biosciences shares dip on $50 million secondary offering

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close

Share document
Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases

Calithera Biosciences Inc (NASDAQ:CALA) shares hit a stumbling block after the company announced the pricing of a $50 million secondary offering late Tuesday.

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close.

Investors responded to the dilutive measure in kind, dropping the share price almost 13% to $4.13.

READ: Pressure BioSciences ultra high-pressure HUB platform shines in food safety studies

The offering is expected to close on June 21. In its Tuesday statement, the company did not specify what it would do with the proceeds.

Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Calithera Biosciences Inc

Price: 2.72 USD

Market: NASDAQ
Market Cap: $146.27 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 48 minutes ago

2 min read